US HCPs: @rAlexPowellMD discusses STRIDE and its data comparing outcomes in in-stent vs native vessel disease.
🔗 View the STRIDE study: https://t.co/GPSYhTiw39
Rx only. Risk: https://t.co/SILdiRZoH4 Clinical results may vary
Yesterday was a monumental day for PE pts & for the space with the FIRST ever RCT reporting outcomes comparing mechanical thrombectomy #CAVT to standard AC in intermediate high risk PE. Results show superiority to AC at effectively & rapidly reversing RV/ LV ratio with a comparable safety profile !
Congratulations & Thank you to #STORM-PE Steering committee & Investigators for their contributions to this landmark trial!
@TCTMD@SIRspecialists@PERTConsortium@PenVascular
US HCPs: Providing more coil and more volume, #RubyXL is designed to offer unmatched efficiency – all through your preferred diagnostic catheter. #NewClassOfCoil#SomethingBIGIsHERE
Rx only. Risk: https://t.co/SILdiRZoH4 Clinical results may vary
#mesocaval shunt was popular, another 4DCT case
Invasive Pancreatic ca, recurrent duodenal GIB. Pt couldn’t be discharged for chemo. Mesocaval shunt allowed for safe discharge and chemotherapy (tolerating well). Blunt Hawkins allowed navigation around stomach/mesentery. #chogazi
US HCPs: With the announcement of EMBOLIZE, Penumbra continues to move the field of embolization forward. This case from Dr. Thomas Khoury shows the value of #MechanicalOcclusion for pelvic venous disorders.
Rx only. Risk info: https://t.co/SILdiRZoH4 Clinical results may vary
US HCPs: Tune in to see Penumbra's coil platform in action. With low recanalization rates, see how #MechanicalOcclusion outperforms thrombus-dependent occlusion. (1, 2) #PackWithPenumbra
Rx only. Risk: https://t.co/SILdiRZoH4 Clinical results may vary.
US HCPs: See us at #VIVAVEINS24 to discuss a retrospective, propensity-matched study of the Vizient Clinical Data Base on how therapies for intermediate-risk PE improve outcomes & optimize healthcare resources #CAVT Rx only. Risk: https://t.co/SILdiRZoH4 Clinical results may vary
US HCPs: NOW is the TIME for Lightning Flash 2.0. The next generation of Penumbra's Computer Assisted Vacuum Thrombectomy platform. #CAVT#NOWISTHETIME
Rx only. Risk info: https://t.co/5m8iyKrIuN Clinical results may vary. | #Sponsored by @penumbrainc@PenVascular
Our CEO, Adam Elsesser, was featured in Newsweek’s “The New Era of Lifesciences” report this week, highlighting how our latest #CAVT will transform clot care. Read more here: https://t.co/79he3pwGkn
Thought-provoking insight from the STRIDE study demonstrating similar high limb salvage rates in male and female patients with LE-ALI. Thank you to the STRIDE investigators for helping gather this important data. #CAVT
US HCPs: ⚡ Check out this #LightningFlash PE case by @drochohan with under 100cc EBL! 🫁 #FeelThePower with #CAVT
Rx only. Risk info: https://t.co/SILdiRZWwC Clinical results may vary
Want to learn how to remove clot in a New York minute? Join us at #VEITHsymposium to hear how the experts are incorporating Computer Assisted Vacuum Thrombectomy (CAVT) into their treatment algorithm. See you in NYC!